Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life in Adults with Hemophilia B after Receiving Gene Therapy with Fidanacogene Elaparvovec

Sylvia von Mackensen, Jonathan M. Ducore, Lindsey A. George, Adam Giermasz, Catherine McGuinn, John E. J. Rasko, Ben J Samelson-Jones, Spencer K. Sullivan, Jerome M. Teitel, Amit Chhabra, Annie F. Fang, Amanda O'Brien, Frank Plonski, Jeremy Rupon, Lynne Smith, Ian Winburn

Blood (2023) 142 (Supplement 1): 3628.

https://doi.org/10.1182/blood-2023-179431

Published: 2023

Journal Articles

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Matthew Mei, Joycelynne Palmer, Ni-Chun Tsai, Hun Ju Lee, Iris Isufi, Leslie L. Popplewell, Lynne Smith, Lacolle Peters, Lara Rodriguez, James Godfrey, John H. Baird, Joo Y. Song, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Alex F. Herrera

Blood (2022) 140 (Supplement 1): 774–776.

https://doi.org/10.1182/blood-2022-167626

Published: 2022

Journal Articles

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood (2022) 139 (25): 3605–3616.

https://doi.org/10.1182/blood.2022015423

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Pallawi Torka, Swetha Kambhampati, Alexandra Muir, Kirsten Orand, Lynne Smith, Alex F. Herrera, Lionel Lewis, Francisco J. Hernandez-Ilizaliturri, Lu Chen, Alexey V. Danilov

Blood (2021) 138 (Supplement 1): 2433.

https://doi.org/10.1182/blood-2021-146345

Published: 2021

Journal Articles

Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a

Andrew D. Leavitt, MD, Barbara A. Konkle, MD, Kimo Stine, MD, Nathan Visweshwar, MD, Thomas J. Harrington, MD, Adam Giermasz, MD PhD, Steven Arkin, MD, Annie Fang, MD PhD, Frank Plonski, RN, MA, Lynne Smith, MBA, Li-Jung Tseng, PhD MBA, Gregory Di Russo, MD, Bettina M Cockroft, MD, Jeremy Rupon, MD, Didier Rouy, MD PhD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-137648

Published: 2020

Journal Articles

Overcoming CD19 Antigen Loss in B-Cell Malignancies with CAR T Cells Targeting BAFF-R

Hong Qin, MD PhD, Zhenyuan Dong, PhD, Xiuli Wang, PhD, Wesley Cheng, BS, Diane Lynne Smith, PhD, Joo Y Song, MD, Ibrahim Aldoss, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 3871.

https://doi.org/10.1182/blood-2019-129228

Published: 2019

Journal Articles

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, Ni-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Ibrahim Aldoss, MD, Vinod A. Pullarkat, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 5729.

https://doi.org/10.1182/blood-2019-131437

Published: 2019

Journal Articles

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, NI-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 4623.

https://doi.org/10.1182/blood-2019-131357

Published: 2019

Journal Articles

Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Hong Qin, MD PhD, Zhenyuan Dong, PhD, Xiuli Wang, PhD, Wesley Cheng, BS, Diane Lynne Smith, PhD, Joo Y Song, MD, Ibrahim Aldoss, MD, Markus Muschen, MD, Stephen J Forman, Larry W Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2018-99-117513

Published: 2018

Journal Articles

Impact of Treatment Regimen with Moroctocog Alfa (AF-CC) on Bleeding Frequency in Pediatric Aged Subjects with Moderately Severe to Severe Hemophilia A

Mark P. Smith, MD FRACP, FRCPA, Jeremy Rupon, MD, Yasser Wali, MD, Hala Remawi, MD, Joan Korth-Bradley, PharmD, PhD, Lynne Smith, MBA, Pablo Rendo, MD

Blood (2018) 132 (Supplement 1): 1205.

https://doi.org/10.1182/blood-2018-99-111891

Published: 2018

Journal Articles

An Open-Label Study of the Safety and Efficacy of Morotocog Alfa (AF-CC) in Previously Untreated Patients Aged <6 Years in Usual Care Settings

Kaan Kavakli, MD, James Baumann, Francois Pierre Huard, MS, MBA, Lynne Smith, MBA, Christine Alvey, Joan Korth-Bradley, PharmD, PhD, Pablo Rendo, MD, Jeremy Rupon, MD

Blood (2017) 130 (Supplement 1): 1091.

https://doi.org/10.1182/blood.V130.Suppl_1.1091.1091

Published: 2017

Journal Articles

CAR-T Cells Targeting BAFF-Receptor for B-Cell Malignancies: A Potential Alternative to CD19

Hong Qin, MD PhD, Zhenyuan Dong, PhD, Fen Wen, MD, Wesley Cheng, BS, Han Sun, PhD, Guowei Wei, PhD, Diane Lynne Smith, PhD, Sattva S. Neelapu, MD, Xiuli Wang, PhD, Stephen J. Forman, MD FACP, Larry W Kwak, MDPhD

Blood (2017) 130 (Supplement 1): 3180.

https://doi.org/10.1182/blood.V130.Suppl_1.3180.3180

Published: 2017

Journal Articles

Novel BAFF-Receptor Antibody to Natively Folded and Glycosylated Recombinant Protein Eliminates Drug Resistant B Cell Malignancies In Vivo

Hong Qin, MD PhD, Guowei Wei, PhD, Ippei Sakamaki, MD PhD, Zhenyuan Dong, PhD, Diane Lynne Smith, PhD, Feng Wen, MS, Han Sun, PhD, Wesley A Cheng, BS, Larry W Kwak, MD PhD

Blood (2016) 128 (22): 468.

https://doi.org/10.1182/blood.V128.22.468.468

Published: 2016

Journal Articles

Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B

Kaan Kavakli, Lynne Smith, Kazimierz Kuliczkowski, MD PhD Prof., Joan Korth-Bradley, Chur Woo You, Joanne Fuiman, Silva Zupancic-Salek, Faraizah Abdul Karim, Pablo Rendo

Blood (2014) 124 (21): 1523.

https://doi.org/10.1182/blood.V124.21.1523.1523

Published: 2014

Journal Articles

Nonacog Alfa: Analysis Of Safety Data From 6 Prospective Clinical Studies In Different Patient Populations With Hemophilia B Treated With Different Therapeutic Modalities

Pablo Rendo, MD, Lynne Smith, MBA, Lee Hsiao-Yu, Frank E. Shafer, MD

Blood (2013) 122 (21): 3604.

https://doi.org/10.1182/blood.V122.21.3604.3604

Published: 2013

Journal Articles

Lack of Seasonal Variation in Bleeding and Patient-Assessed Pain Patterns in Patients with Hemophilia B Receiving On-Demand Therapy

Frank E. Shafer, MD, Lynne Smith, MBA, Nicholas Vendetti, MS, Pablo Rendo, MD, Marcus E. Carr, MD

Blood (2012) 120 (21): 1136.

https://doi.org/10.1182/blood.V120.21.1136.1136

Published: 2012

Journal Articles

Evaluation of Two Secondary Prophylaxis Regimens of Recombinant Factor IX(r-IX) in Moderately Severe to Severe( FIX ≤2%) Hemophilia B Patients

Pablo Rendo, MD, Mary-Kate Barrette-Grischow, MA, MPH, Lynne Smith, MBA, JM Korth-Bradley, Robert Charnigo, Frank E. Shafer, MD

Blood (2012) 120 (21): 4628.

https://doi.org/10.1182/blood.V120.21.4628.4628

Published: 2012

Journal Articles

Pharmacokinetic/Pharmacodynamic Assessment of Reformulated Recombinant Coagulation Factor IX in Adults and Children with Severe Hemophilia B

JM Korth-Bradley, Leonard A. Valentino, MD, FAAP, Pablo Rendo, MD, Frank E. Shafer, MD, Lynne Smith, James A. Baumann, Robert Charnigo

Blood (2011) 118 (21): 1190.

https://doi.org/10.1182/blood.V118.21.1190.1190

Published: 2011

Journal Articles

Phase I Study of Noscapine for Patients with Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy.

Anil Tulpule, MD, Alexandra M. Levine, MD, Nancy E. Berman, RN, BSN, Lynne Smith, PhD, Alan Auerbach, Dan Douer, MD

Blood (2005) 106 (11): 3341.

https://doi.org/10.1182/blood.V106.11.3341.3341

Published: 2005

Journal Articles

Results of a Pilot Trial of Fludarabine, Mitoxantrone and Rituxan in Mantle Cell Lymphoma.

Alexandra M. Levine, MD, Anil Tulpule, MD, Lynne Smith, PhD, Byron M. Espina, AB, Ann F. Mohrbacher, MD, Donald I. Feinstein, MD

Blood (2005) 106 (11): 945.

https://doi.org/10.1182/blood.V106.11.945.945

Published: 2005

NARROW

Health-Related Quality of Life in Adults with Hemophilia B after Receiving Gene Therapy with Fidanacogene Elaparvovec

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a

Overcoming CD19 Antigen Loss in B-Cell Malignancies with CAR T Cells Targeting BAFF-R

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Impact of Treatment Regimen with Moroctocog Alfa (AF-CC) on Bleeding Frequency in Pediatric Aged Subjects with Moderately Severe to Severe Hemophilia A

An Open-Label Study of the Safety and Efficacy of Morotocog Alfa (AF-CC) in Previously Untreated Patients Aged <6 Years in Usual Care Settings

CAR-T Cells Targeting BAFF-Receptor for B-Cell Malignancies: A Potential Alternative to CD19

Novel BAFF-Receptor Antibody to Natively Folded and Glycosylated Recombinant Protein Eliminates Drug Resistant B Cell Malignancies In Vivo

Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B

Nonacog Alfa: Analysis Of Safety Data From 6 Prospective Clinical Studies In Different Patient Populations With Hemophilia B Treated With Different Therapeutic Modalities

Lack of Seasonal Variation in Bleeding and Patient-Assessed Pain Patterns in Patients with Hemophilia B Receiving On-Demand Therapy

Evaluation of Two Secondary Prophylaxis Regimens of Recombinant Factor IX(r-IX) in Moderately Severe to Severe( FIX ≤2%) Hemophilia B Patients

Pharmacokinetic/Pharmacodynamic Assessment of Reformulated Recombinant Coagulation Factor IX in Adults and Children with Severe Hemophilia B

Phase I Study of Noscapine for Patients with Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy.

Results of a Pilot Trial of Fludarabine, Mitoxantrone and Rituxan in Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only